Floatz logo

cd19/cd20/bcma car-t

Relapsed

Shanghai Cell Therapy Group Co.,LtdCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Relapsed cohort.

Asset / SponsorPhaseRating
Epirubicin
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Chimeric Antigen Receptor Modified T Cells Infusion
Henan Cancer Hospital
Phase 1CC
cd19/cd22-bispecific car-t cells
Henan Cancer Hospital
Phase 1CC
Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
N/AD

Same molecule, other indications

cd19/cd20/bcma car-t is also rated in:

RefractoryDormant
C
Indicative ·
38 / 100
View asset →
Multiple MyelomaDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →